Phaseline

Companies › Imunon

Imunon: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
IMNN-001 (GEN-1)
IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer
IL12Phase 3Epithelial Ovarian Cancer; Ovarian CancerJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03393884IMNN-001 (GEN-1)Phase 1Epithelial Ovarian CancerOncologyJul 2024
NCT05739981IMNN-001 (GEN-1)Phase 1Ovarian CancerOncologyJun 2027
NCT06915025IMNN-001 (GEN-1)Phase 3Epithelial Ovarian CancerOncologyOct 2032

From the company's SEC filings

Cash and short-term investments of $7m on 2026-06-30; operating cash outflow about $14m a year; runway about 6 months at that burn, to Dec 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

IL12 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences VLP Therapeutics Sonnet BioTherapeutics Kangabio AUSTRALIA enGene Inovio Pharmaceuticals Trogenix

Companies built like this

Genelux BriaCell Therapeutics Actinium Pharmaceuticals Oncolytics Biotech Cardiff Oncology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.